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Rosiglitazone is a PPARg agonist commonly used to
treat diabetes. In addition to improving insulin sensi-
tivity, rosiglitazone restores normal vascular function
by a mechanism that remains poorly understood.
Herewe show that adiponectin is required tomediate
the PPARg effect on vascular endotheliumof diabetic
mice. In db/db and diet-induced obese mice, PPARg
activation by rosiglitazone restores endothelium-
dependent relaxation of aortae, whereas diabetic
mice lacking adiponectin or treated with an anti-
adiponectin antibody do not respond. Rosiglitazone
stimulates adiponectin release from fat explants,
and subcutaneous fat transplantation from rosiglita-
zone-treated mice recapitulates vasodilatation in
untreated db/db recipients. Mechanistically, adipo-
nectin activates AMPK/eNOS and cAMP/PKA
signaling pathways in aortae, which increase NO
bioavailability and reduce oxidative stress. Taken
together, these results demonstrate that adipocyte-
derived adiponectin is required for PPARg-mediated
improvement of endothelial function in diabetes.
Thus, the adipose tissue represents a promising
target for treating diabetic vasculopathy.
INTRODUCTION
Obesity and diabetes are common risk factors for the initiation of
vascular dysfunction. Adipose tissue is now recognized as an
important metabolic and endocrine organ in the regulation of
glucose metabolism. Dysregulation of adipose tissue partici-
pates in the development of insulin resistance and vascular
complications of diabetes (Hajer et al., 2008).104 Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc.The gene expression pattern of adiponectin in subcutaneous
and visceral adipose tissue and the levels of circulating adipo-
kines predict insulin resistance and diabetic risk (Samaras
et al., 2010). Although obesity is a common contributor to insulin
resistance, the molecular link between increased adiposity and
impaired vascular function in humans is not fully elucidated.
Adipose tissue also contributes to the regulation of vascular
tone (Fe´su¨s et al., 2007; Ga´lvez-Prieto et al., 2008; Verlohren
et al., 2004). Chronic inflammation of adipose tissue leads to
vascular dysfunction due to a diminished production of vasopro-
tective cytokines and increased release of inflammatory cyto-
kines by adipocytes. However, the role, if any, of adipose tissue
in vascular benefit of antidiabetic drugs is largely unclear.
Adiponectin is an adipose-secreted protein that exerts both
antiatherogenic and insulin-sensitizing effects, and a reduced
production of adiponectin is closely coupled to insulin resistance
(Kadowaki et al., 2006; Whitehead et al., 2006; Zhu et al., 2008).
The plasma concentration of adiponectin in obese subjects is
lower than that in nonobese subjects and inversely correlates
with body mass index (Arita et al., 1999). Moreover, hypoadipo-
nectinemia is associated with reduced endothelium-dependent
dilatation in both diabetic and nondiabetic human subjects
(Ouchi et al., 2003; Shimabukuro et al., 2003; Tan et al., 2004;
Torigoe et al., 2007). The nuclear transcription factor peroxisome
proliferator-activated receptor-g (PPARg) is a major regulator of
adipocyte function and controls the secretion of adipokines, in
particular promoting the production of adiponectin (Anghel
et al., 2007;Crossnoet al., 2006;Maeda et al., 2001)while limiting
the generation of proinflammatory TNF-a, IL-6, and IL-1b (Jiang
et al., 1998). The insulin-sensitizing drugs thiazolidinediones
(TZDs), including rosiglitazone and pioglitazone, are high-affinity
ligands that act on PPARg in liver, skeletal muscle, and adipose
tissue. TZDs also increase plasma adiponectin levels in insulin-
resistant humans (Yang et al., 2002; Zhu et al., 2008). PPARg
ligands improve endothelial function through multiple mecha-
nisms, including stimulation of eNOS (Calnek et al., 2003; Cho
et al., 2004; Yasuda et al., 2009), inhibition of inflammatory target
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Figure 1. Adipose Tissue Is Required for PPARg Activation-Induced Amelioration of the Impaired Endothelium-Dependent Relaxations in
db/db Mouse Aortae
(A) Procedure of fat explant experiments.
(B) Acetylcholine-induced endothelium-dependent relaxations in db/db aortae after incubation in culture medium from rosiglitazone-treated fat explants (pool of
subcutaneous, visceral, and perivascular fats) from db/db and db/m+ mice.
(C) Effect of 12 hr exposure of db/db mouse aortae to 1 mmol/l rosiglitazone alone. Results are means ± SEM of 6–8 experiments from different mice.
(D) Effect of 12 hr incubation of fat explant from subcutaneous adipose tissue from db/db mouse with 1 mmol/l rosiglitazone. Results are means ± SEM of 6–8
experiments from different mice.
(E) Effect of 12 hr incubation of fat explant from visceral adipose tissue from db/db mouse with 1 mmol/l rosiglitazone. Results are means ± SEM of 6–8
experiments from different mice.
(F) Effect of 12 hr incubation of fat explant from perivascular adipose tissue from db/db mouse with 1 mmol/l rosiglitazone. Results are means ± SEM of 6–8
experiments from different mice.
(G) The protein expression of PPARg in subcutaneous, visceral, and perivascular adipose tissues from db/m+ and db/dbmice. Results are means ± SEM of four
experiments.
(H) The levels of adiponectin present in culture medium after incubation of subcutaneous, visceral, and perivascular fat explants with rosiglitazone. Results are
means ± SEM of four experiments. *p < 0.05 versus control within each group.
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Adiponectin and Endothelial Functiongenes (Kanda et al., 2009; Lee et al., 2009; Orasanu et al., 2008),
and downregulation of NAD(P)H oxidases (Ceolotto et al., 2007).
Although TZDs are widely used to restore insulin sensitivity in
patients with type 2 diabetes (Yki-Ja¨rvinen, 2004), the molecular
mechanisms that confer their vascular protection are poorly
understood. The present experiments were designed to test
the hypothesis that adipocyte-derived adiponectin plays an
indispensable role in the amelioration of endothelial dysfunction
in diabetes following chronic treatment with PPARg agonists.
The present results demonstrate that subcutaneous adipose
tissue is an important target for PPARg agonists to improve
diabetic endothelial function. Adipocyte-derived adiponectinpreserves the bioavailability of nitric oxide (NO) by two indepen-
dent cellular mechanisms.
RESULTS
Adipose Tissue Is Required for PPARg Activation-
Induced Restoration of Endothelial Function in db/db
Mouse Aortae
In order to reveal the role of adipose tissue in PPARg-induced
endothelial protection in vivo, an ex vivo fat explant organ culture
method is used to examine the effect of adipokines fromdifferent
fat depots on vascular function (Figure 1A). RosiglitazoneCell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc. 105
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Figure 2. Role of Adiponectin in PPARg Agonist-
Induced Vascular Benefit in db/db Mice
(A and B) Anti-adiponectin antibody (anti-Adn, 5 mg/ml)
and GW9662 (5 mmol/l, PPARg antagonist) abolished the
effect of PPARg-activated subcutaneous fat explants by
rosiglitazone (db/m+, A; db/db, B) to improve the EDR in
aortae from db/db mice.
(C) EDR of aortae from db/db mice did not improve after
incubation in medium of fat explants from adiponectin/
(Adn/) mice treated with rosiglitazone.
(D) The levels of adiponectin present in culture medium
from fat explants under identical procedures as described
in (A)–(C).
(E) Effect of rosiglitazone-treated subcutaneous fat ex-
plants from PPARg+/ mice on EDR in aortae from db/db
mice.
(F) The expression of PPARg and adiponectin release from
fat explants of PPARg+/ mice. Results are means ± SEM
of 4–6 experiments. *p < 0.05 versus control, #p < 0.05
versus rosiglitazone.
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Adiponectin and Endothelial Function(1 mmol/l, 12 hr)-activated adipose tissue (pool of subcutaneous,
visceral, and perivascular fats) from either db/m+ or db/db mice
significantly improved endothelium-dependent relaxations
(EDRs) in db/db mouse aortae (Figure 1B), while 12 hr exposure
of isolated db/db mouse aortae to rosiglitazone alone did not
improve EDRs (Figure 1C). The EDRs were increased markedly
only by medium from rosiglitazone-activated subcutaneous
adipose tissue (Figure 1D), while medium from visceral adipose
tissue had no effect (Figure 1E), and that from perivascular
adipose tissue caused a moderate potentiation of EDRs (Fig-
ure 1F). Endothelium-independent relaxations to sodium nitro-
prusside (SNP) were similar in aortic rings from all the groups
(Figure S1A).
Adipose tissue from db/db mice expressed significantly less
PPARg. The expression level of PPARg corresponded to the
effect on EDRs from different fat depots of db/db and db/m+
mice. Subcutaneous fat expressed the highest level of PPARg,
followed by perivascular fat, while visceral fat contained the least
amount of PPARg (Figure 1G). The adiponectin release in
response to rosiglitazone in subcutaneous fat was significantly
higher than in perivascular or visceral fat from db/db mice (Fig-
ure 1H). The following experiments were performed using only
subcutaneous fat from db/db mice in organ culture.106 Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc.Adiponectin and Vascular Effects
of Rosiglitazone
We next tested the effects of PPARg antagonist
GW9662 and anti-adiponectin neutralizing
antibody to establish an essential role of adi-
pose tissue-derived adiponectin in mediating
PPARg-dependent improvement of EDRs in
db/db mice. Both anti-adiponectin antibody
(5 mg/ml) and GW9662 (5 mmol/l) prevented the
effect of PPARg-activated fat explant from
db/db (Figure 2A) and db/m+ mice (Figure 2B).
The role of adipocyte-derived adiponectin was
further confirmed as EDR in db/db mice was
not restored by rosiglitazone-treated fat explant
from Adn/ mice (Figure 2C). Rosiglitazone
elevated the amounts of adiponectin released by fat explants
from db/db and db/m+ mice but not from Adn/ mice, and
this increase was inhibited by GW9662 (Figure 2D). Finally, we
verified the role of PPARg using PPARg+/ mice. Rosiglita-
zone-stimulated adiponectin release was much less in fat
explants from PPARg+/ mice, which might account for small
improvement of EDRs in db/db mouse aortae, correlating with
less PPARg expression (Figures 2E and 2F).
Fat Transplantation In Vivo Improves Endothelial
Function in Diabetic Mice
To further confirm the importance of subcutaneous fat in endo-
thelial protection in response to PPARg activation, we performed
fat transplantation experiments in diabetic mice. This was done
using subcutaneous flank fat of donor db/db mice, removing
a similar amount of subcutaneous fat of recipient db/db mice,
and placing the fat grafts into the same dorsal subcutaneous
area from the donor to the recipient (Figure 3A). Some donors
or recipients were treated with rosiglitazone (10 mg/kg/day for
4 weeks) prior to fat transplantation. EDRs were improved in
control recipient mice receiving fat graft from rosiglitazone-
treated mice (C+RF) (Figure 3B). Rosiglitazone-treated recipient
mice receiving fat graft from either rosiglitazone-treated donors
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Figure 3. Fat Transplantation from Rosiglitazone-Treated db/db
Mice Improves Endothelial Function in Control db/db Mice
(A) Schematic of fat transplantation procedure.
(B) Improved EDR observed in aortae from rosiglitazone-treated db/db mice
receiving fat grafts from either control (R+CF) or rosiglitazone-treated db/db
mice (R+RF) and also from control db/db mice receiving fat grafts from rosi-
glitazone-treated db/db mice (C+RF), compared with the impaired EDR from
control db/db mice (C+CF). Results are means ± SEM of six mice. *p < 0.05
versus C+CF.
(C) Plasma adiponectin level in all the groups of db/db mice. Results are
means ± SEM of 3–4 mice. *p < 0.05 versus C+CF.
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Adiponectin and Endothelial Function(R+RF) or from control donors (R+CF) had EDRs similar to C+RF
littermates, which were also improved compared with those
from control recipients receiving fat grafts from control donor
mice (C+CF) (Figure 3B). Plasma adiponectin concentration
also increased significantly in C+RF, R+CF, and R+RF groups
compared to those from C+CF group (Figure 3C).
In Vivo Rosiglitazone Treatment Improves Endothelial
Function via Adiponectin-Dependent Mechanisms
EDRs in aortae were reduced in db/db compared to db/m+mice
(Figures 4A and 4B). Administration of db/dbmice with rosiglita-
zone (10 mg/kg body weight/day) for 4 weeks potentiated EDRs
in their aortae, but not in those from db/Adn/ DKO mice
(Figures 4A and 4B), while the glucose tolerance test showed
similar improvement in both db/db and db/Adn/ DKO mice
after rosiglitazone treatment (Figures 4C and 4D). Rosiglitazone
treatment in db/db mice also increased the plasma adiponectin
level (2.86 ± 0.22 mg/ml in vehicle-treated mice versus 8.08 ±
1.45 mg/ml in rosiglitazone-treated mice, p < 0.05). Aortae from
db/db mice exhibited fewer phosphorylations of AMPKa at
Thr172 and eNOS at Ser1177 compared with those from db/
m+ mice, which were restored by in vivo rosiglitazone treatment
(Figures 4E–4G).
Aortae from db/db mice showed less expression of AdipoR2
but not AdipoR1 compared to those from db/m+ mice (Figures
4E, 4H, and 4I). Rosiglitazone treatment increased AdipoR2
expression in aortae from db/dbmice without affecting AdipoR1
expression (Figures 4E, 4H, and 4I).Effect of PPARg and Adiponectin in Diet-Induced Obese
Mice
To verify the effect of rosiglitazone in another mouse model of
diabetes, experiments were performed in high-fat-diet-induced
obese (DIO) mice. Aortae from DIO mice exhibited reduced
EDR compared with age-matched C57BL/6J littermates, while
endothelium-independent relaxations to SNP were unaltered
(Figure S1B). After 12 hr incubation in medium collected from
fat explants of DIO mice treated with rosiglitazone, EDRs were
improved (Figure 5A) and were inhibited by GW9662. Improved
EDRs correlated to the adiponectin concentrations in the
medium (Figure 5B). Similar results were obtained with troglita-
zone or ciglitazone treatment (Figures S2B–S2D). Rosiglitazone
treatment in vivo of DIO mice (10 mg/kg/day, 2 weeks) normal-
ized the EDRs in their aortae and increased plasma adiponectin
level (Figures 5C and 5E). In addition, the improved EDRs after
in vivo rosiglitazone treatment were inhibited by overnight incu-
bation with compound C or anti-adiponectin antibody, but not
by GW9662 (Figure 5D). The reduced phosphorylation of AMPKa
and eNOS in aortae from DIO mice increased after rosiglitazone
treatment (Figures 5F and 5G).
Adiponectin Increases NO Bioavailability through AMPK
and PKA
Adiponectin (5 mg/ml) augmented EDR in db/db mouse aortae
(Figure 6A). Such effect was abolished by anti-adiponectin anti-
body (Figure 6A) and inhibited by compound C (Figure 6B), but
unaffected by GW9662 (Figure 6A). A similar effect was also
observed using aortae from DIO mice (Figure S3). Treatment
with PKA inhibitors, H89 (1 mmol/l) or Rp-cAMP (10 mmol/l),
and adenylyl cyclase inhibitor SQ22536 (10 mmol/l) attenuated
the effect of adiponectin (Figure 6C). Combined treatment with
compoundC andH89 did not cause further inhibition (Figure 6B).
Adiponectin increased the phosphorylation of AMPKa at Thr172
and eNOS at Ser1177. Compound C but not H89 inhibited
adiponectin-stimulated AMPKa phosphorylation (Figure 6D).
Compound C and SQ22536 also attenuated adiponectin-stimu-
lated eNOS phosphorylation (Figure 6E).
The aortae of db/db mice contained higher levels of ROS
compared with those of db/m+mice, as revealed by DHE fluores-
cencestaining. Treatmentwithadiponectin reducedROS,and this
effect was abolished byH89 or SQ22536, but not by compoundC
(Figures 7A and 7B). Forskolin, a cyclic AMP-elevating agent
(100 nmol/l), produced an effect similar to adiponectin in reducing
ROS (Figures 7A and 7B). Both adiponectin and forskolin raised
the tissue content of cyclic AMP in db/m+ and db/db mouse
aortae. Only SQ22536, but not the other inhibitors, prevented
the adiponectin-induced increase in cyclic AMP level (Figure 7C).
The NO production in response to A23187 (1 mmol/l) was
blunted in primary mouse aortic endothelial cells incubated in
high glucose (30 mmol/l, HG) when compared with mannitol
control (NG) (Figures 7D and 7E). Incubation of 5 mg/ml adipo-
nectin restored the reduced NO production under high-glucose
condition (Figures 7D and 7E).
DISCUSSION
The present study defines an obligatory role of adipose tissue,
particularly subcutaneous fat depots, in an improvement ofCell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc. 107
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Figure 4. In Vivo Rosiglitazone Treatment Improves Endothelial Function in Diabetic Mice through Adiponectin-Dependent Mechanism
(A and B) Chronic treatment with rosiglitazone improved EDR in aortae from db/db mice. Potentiation of EDR was abolished in aortae from db/Adn DKO mice.
(C and D) Oral glucose tolerance test showed that rosiglitazone treatment improved glucose tolerance in both db/db and db/Adn DKO mice.
(E–G)Western blotting showed the AMPKa and eNOSphosphorylation with total AMPKa and eNOS levels in aortae from db/dbmice after rosiglitazone treatment.
(H and I) Western blotting showed the expressions of AdipoR2 and AdipoR1 in aortae from the three groups of mice. Results are means ± SEM of six mice.
*p < 0.05 versus db/m+, #p < 0.05 versus db/db, yp < 0.05 versus db/db + Rosiglitazone, and $p < 0.05 versus db/Adn DKO.
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Adiponectin and Endothelial Functionendothelial function in diabetic mice following PPARg activation.
It demonstrates that adipocyte-derived adiponectin is the
primary mediator that improves endothelial function and does
so by both AMPK- and PKA-dependent mechanisms. The
present findings suggest that adipose tissue can be an important
therapeutic target in the protection of vascular dysfunction in
diabetes by producing and releasing anti-inflammatory vaso-
active hormones, among which adiponectin plays an indispens-
able role in protecting vascular function.
The present study employs multiple approaches, aided by
the use of relevant genetically modified mice, to demonstrate108 Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc.a crucial role of adipocyte-derived adiponectin in PPARg
agonist-induced endothelial cell protection in db/db and DIO
mice. Differential expression levels of PPARg in the three fat
depots were observed, with PPARg expression being most
abundant in subcutaneous, intermediate in perivascular, and
least in visceral adipose tissues. The PPARg level positively
correlated with the amount of adiponectin released upon PPARg
activation and the extent of improvement of EDR in aortae from
db/dbmice. The present results indicate that PPARg agonists do
not act on the endothelium directly, since exposure to rosiglita-
zone did not augment the EDR without the presence of adipose
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Figure 5. Role of Adiponectin in PPARg
Agonist-Induced Vascular Benefit in DIO
Mice
(A) EDRs in aortae from DIO mice improved after
treatment in the medium collected from fat explant
of DIO mice incubated with rosiglitazone (1 mmol/l,
12 hr) and inhibited by GW9662 (5 mmol/l, 12 hr).
(B) Rosiglitazone (1 mmol/l, 12 hr)-increased adi-
ponectin release in the medium of fat explant and
inhibited by GW9662 (5 mmol/l, 12 hr). *p < 0.05
versus control, #p < 0.05 versus rosiglitazone.
(C) Rosiglitazone treatment in vivo improved EDR
in aortae from DIO mice. *p < 0.05 versus C57,
#p < 0.05 versus DIO control.
(D) Improved EDR in aortae from rosiglitazone-
treated DIO mice were inhibited by compound C
(5 mmol/l) and anti-adiponectin antibody (Adn-Ab,
5 mg/ml) but unaffected by GW9662 (5 mmol/l).
*p < 0.05 versus control.
(E) Rosiglitazone treatment increased plasma
adiponectin concentration. *p < 0.05 versus DIO.
(F and G) Western blots showed the increased
AMPKa and eNOS phosphorylation in aortae from
DIO mice after rosiglitazone treatment. *p < 0.05
versus C57, #p < 0.05 versus DIO. Results are
means ± SEM of six mice.
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Adiponectin and Endothelial Functiontissue. Although adipose tissue from db/dbmice expressed less
PPARg and secreted less adiponectin than those from db/m+
mice, PPARg activation in subcutaneous fat explants from
db/db mice shows similar effectiveness in augmenting the EDR
in db/db mouse aortae. The specificity of PPARg was further
verified by using PPARg antagonist and aortae from PPARg+/
mice. The obligatory role of adipocyte-derived adiponectin in
the vascular benefit of PPARg agonist is supported by the obser-
vation that a neutralizing anti-adiponectin antibody in vitro could
eliminate the beneficial effect of PPARg-activated fat explants
and that PPARg activation in fat explants from adiponectin/
mice failed to improve the EDR of db/db mouse aortae.
The benefit of PPARg activation is further confirmed by the
chronic oral administration of rosiglitazone to diabetic mice.
Rosiglitazone treatment augmented EDR in aortae from db/db
mice, improved glucose tolerance, and increased plasma adipo-
nectin level. Since the vascular benefit could be a consequence
of systemic improvement of insulin sensitivity in diabetic mice
after rosiglitazone treatment, db/Adn DKO mice were used to
verify the adiponectin-dependent endothelial protection of
in vivo PPARg activation. The potentiating effect of rosiglitazone
on endothelial function was blunted in aortae of these animals,
indicating an indispensable role of adiponectin in preventing
diabetic vascular dysfunction.Cell Metabolism 14, 104To confirm the role of adipose tissue in
response to PPARg activation in diabetic
mice, we examined whether or not the
benefit of PPARg activation in adipose
tissue on endothelial function can also
be transferred. Visceral fat removal or
subcutaneous fat transplantation is effec-
tive to reverse or prevent insulin resis-
tance and glucose intolerance in diabeticmice (Gabriely et al., 2002; Gavrilova et al., 2000; Tran et al.,
2008). The present results showed that fat grafts from rosiglita-
zone-treated db/db mice improved endothelial function after
implanting them into untreated db/db mice. This benefit
lasted in the recipient mice for 2 weeks after the rosiglitazone
treatment stopped. This approach strengthened the hypothesis
that subcutaneous fat is the major source for the release of adi-
ponectin in response to PPARg activation in diabetic mice.
TZDs are reported to stimulate adiponectin transcription
through a PPAR-responsive element in its promoter in adipo-
cytes and in adipose tissues of obese mice and promote adipo-
nectin secretion from adipocytes (Combs et al., 2002; Iwaki
et al., 2003; Maeda et al., 2001; Yang et al., 2004). The present
study demonstrates an increased adiponectin release from fat
explants upon PPARg activation. Although the PPARg expres-
sion was less in adipose tissue from db/dbmice, PPARg activa-
tion in fat explants from these mice showed an effectiveness to
release adiponectin similar to fat from nondiabetic mice. A
possible explanation is that TZDs improve insulin sensitivity
and reverse the proinflammatory changes in adipocytes to
facilitate the release of vasoprotective adipokines (Chatterjee
et al., 2009; Chui et al., 2005; He et al., 2003; Marchesi et al.,
2009; Nawrocki et al., 2006). In addition, we treated DIO mice
and found that rosiglitazone treatment produced comparable–115, July 6, 2011 ª2011 Elsevier Inc. 109
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(A) Adiponectin (Adn, 5 mg/ml) alleviated the impaired EDR
in db/db mouse aortae, and this effect was reversed by
anti-adiponectin antibody (Anti-Adn Ab, 5 mg/ml), but
unaffected by GW9662 (5 mmol/l).
(B) Effects of compound C (5 mmol/l) and compound C plus
H89 (1 mmol/l).
(C) Effects of H89 (1 mmol/l), Rp-cAMP (10 mmol/l), or
SQ22536 (100 mmol/l).
(D) Adiponectin (5 mg/ml) increased the phosphorylation of
AMPKa at Thr172, which was inhibited by compound C.
(E) Adiponectin (5 mg/ml) increased the phosphorylation of
eNOS at Ser1177, which was inhibited by compound C
and SQ22536. Results are means ± SEM of 4–6 experi-
ments. *p < 0.05 versus Control, #p < 0.05 versus adipo-
nectin. Control group and Adn group in (A)–(C) are from the
same data but separated in different graphs for a clearer
presentation.
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Adiponectin and Endothelial Functionbenefits in improving endothelial function and enhancing the
release of adiponectin. Like rosiglitazone, two other PPARg
agonists, ciglitazone and troglitazone in the fat explant culture
experiments, exhibited similar actions, further supporting the
essential role of adiponectin in the improvement of EDR in
aortae from both db/db and obese mice in response to PPARg
stimulation.
Treatment with TZDs improves cardiovascular outcomes such
as hypertension and atherosclerosis (Calkin et al., 2005; Collins
et al., 2001; Joner et al., 2007; Ryan et al., 2004; Wang et al.,
2004; Yue Tl et al., 2001). In vivo TZD treatment, through adipo-
nectin-dependent mechanisms, reduces pathological revascu-
larizations in the ischemic retina (Higuchi et al., 2010) and inhibits
plasminogen activator inhibitor-1 production (Hoo et al., 2007).
The present study suggests that the vascular benefit of TZD
treatment is largely dependent on adiponectin instead of
a systemic improvement of insulin sensitivity, since the glucose
tolerance of db/db and db/Adn DKO mice improved to a similar
extent after rosiglitazone treatment, but EDRs were improved by
the treatment only in the former. However, direct long-term
beneficial effects of TZDs on endothelial cells and vascular
smooth muscle cells cannot be excluded. Indeed, several
studies suggest that TZDs also act directly on the vasculature
to exert anti-inflammatory and antioxidative effects by inhibition
of the production of TNF-a and matrix metalloproteinase 9 and
of the expression of IkBa (Bishop-Bailey et al., 2002; Chang
et al., 2009; de Dios et al., 2003; Goetze et al., 2002; Law
et al., 2000; Marx et al., 1998; Orasanu et al., 2008). In type 2
diabetic patients, TZDs also have anti-inflammatory effects
by reducing monocyte chemoattractant protein-1, C-reactive
protein, and vascular cell adhesion molecules-1 (Ghanim et al.,110 Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc.2006; Hanefeld et al., 2007; Kahn et al., 2010;
Kanda et al., 2009; Lombardi et al., 2008; Marx
et al., 2003; Mohanty et al., 2004). The present
results do not indicate a de novo role for endo-
thelial PPARg in mediating adiponectin-induced
effects, because PPARg antagonists did not
reverse the adiponectin-induced restoration of
EDR in aortae from both db/db and DIO mice(Figures S4A and S4C) nor affected the improved EDR in aortae
from rosiglitazone-treated DIO mice (Figure S4B).
To further investigate the direct effect of adiponectin on
vascular function, the effect of full-length mouse recombinant
adiponectin was studied. The observations that adiponectin
augmented EDR, increased AMPKa and eNOS phosphorylation,
and reduced ROS production in aortae from db/dbmice suggest
that both AMPK and cyclic AMP/PKA signaling cascades
contribute to the effect of adiponectin in increasing NO bioavail-
ability. The present findings are in line with the observation that
AMPK activation is involved in adiponectin-stimulated produc-
tion of NO in cultured endothelial cells (Chandrasekar et al.,
2008; Chen et al., 2003; Cheng et al., 2007; Deng et al., 2010;
Ouchi et al., 2004). We demonstrate the functional importance
of AMPK activity in adiponectin-induced vascular benefit in
intact arteries of diabetic mice.
The adiponectin-induced improvement of EDR can also be
mediated by the cyclic AMP/PKA cascade. This conclusion is
based on the observation that the responses of db/db mouse
aortae to adiponectin were inhibited by inhibitors of adenylyl
cyclase and PKA. These agents also reduced eNOS phosphory-
lation. Further experiments demonstrated that adiponectin
increased the cyclic AMP content in db/db mouse aortae
through activation of adenylyl cyclase, independently of AMPK.
Importantly, PKA was also involved in the adiponectin-induced
ROS reduction in aortae from db/db mice. These findings
suggest that the vascular effect of adiponectin is also partially
mediated through PKA. Previous studies in human endothelial
cells showed that cyclic AMP/PKA signaling mediates the inhib-
itory effect of adiponectin on high-glucose-induced H2O2 gener-
ation (Ouedraogo et al., 2006). In patients, hypoadiponectinemia
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Figure 7. Adiponectin Reduces ROS Generation and Increases NO Bioavailability
(A and B) Representative pictures (A) and summarized data (B) showing adiponectin (5 mg/ml)-reduced ROS accumulation as determined by DHE fluorescence in
the vascular wall of aortae from db/db mice, and this effect was reversed by H89 or SQ22536, but not by compound C, with forskolin as positive control.
(C) Adiponectin (5 mg/ml) increased the production of cyclic AMP in aortae from db/db mice, which was inhibited by SQ22536, but not by H89 or compound C.
(D and E) Representative images and summarized data showing that adiponectin (5 mg/ml) enhanced the NO production in response to 1 mmol/l A23187 under
high-glucose (30 mmol/l, HG) condition. Results are means ± SEM of six experiments. *p < 0.05 versus control within each group, #p < 0.05 versus adiponectin
(Adn). NG, normal glucose (5 mmol/l glucose + 25 mmol/l mannitol).
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Adiponectin and Endothelial Functionis associated with increased oxidative stress (Lautama¨ki et al.,
2007), suggesting the major involvement of the cyclic AMP/PKA
pathway in lowering ROS. However, the possibility cannot bediscounted that in vivo TZD treatment results in direct inhibition
of oxidative stress, as activation of endothelial PPARg also
exerts anti-inflammatory and antioxidant effects (Beyer et al.,Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc. 111
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Adiponectin and Endothelial Function2008; Ceolotto et al., 2007). Moreover, the antioxidative effect of
adiponectin may also be due to the inhibition of NADPH oxidase
activity, suppression of IkBa expression, and antagonism of
TNF-a (Devaraj et al., 2008; Li et al., 2007; Sharma et al., 2008;
Tao et al., 2007; Wang et al., 2009; Zhang et al., 2010).
Several previous reports suggest that adiponectin receptors
AdipoR1 and AdipoR2 are expressed in endothelial cells (Cheng
et al., 2007; Goldstein and Scalia, 2004; Tan et al., 2004). In
bovine endothelial cells, AdipoR1 has higher affinity for globular
adiponectin, while AdipoR2 has similar affinity for both globular
and full-length adiponectin, which was used in the present
experiments (Motoshima et al., 2004). In human endothelial cells,
both AdipoR1 and AdipoR2 mediate the effect of adiponectin to
stimulate eNOS activity (Cheng et al., 2007). The expressions of
both receptors have also been observed in aortae of db/dbmice
(Zhang et al., 2010). The present study found that AdipoR2
expression was reduced in aortae from db/db mice compared
with db/m+ mice and increased after rosiglitazone treatment,
while AdipoR1 was unaltered. The results indicate additional
benefit of PPARg activation through restoring the reduced
AdipoR2 expression in diabetic mouse arteries. The present
findingsmay help to explain that the reduced sensitivity to adipo-
nectin in diabetic mouse arteries (Cheng et al., 2007) may be
related to the decreased expression of AdipoR2.
In summary, the present study with focus on this ‘‘adipose-
vascular loop’’ demonstrates that PPARg-activated, adipose
tissue-derivedadiponectinplaysanobligatory role inTZD-induced
improvement of endothelial function in diabetes. Adiponectin
increases the NO bioavailability by activating AMPK and cyclic
AMP/PKA signaling. The present results also support a differential
role of various fat depots, which is directly related to the amount of
adiponectin released upon PPARg activation. Adipose tissue
could be an important intervention target for newly developed
PPARg agonists in the alleviation of diabetic vasculopathy.EXPERIMENTAL PROCEDURES
Animals
We used male leptin receptor/ (db/db) mice and leptin receptor//
adiponectin/ double knockout (db/Adn DKO) mice (Zhou et al., 2008) and
their lean littermates, adiponectin knockout (Adn/) mice (Ma et al., 2002)
with a C57BL/6J background and their wild-type controls, and PPARg hetero-
zygous-deficient (PPARg+/) and wild-type mice (Yu et al., 2008). PPARg+/
mice were used because all homozygous PPARg knockout animals were
embryonically lethal due to placental dysfunction (Yu et al., 2008). The mice
were housed in a temperature-controlled holding room (22C–23C) with
a 12 hr light/dark cycle and fed a diet of standard chow and water. All of the
experiments were conducted under the institutional guidelines for the humane
treatment of laboratory animals. DIOmice were generated by C57BL/6J, at the
age of 6–7 weeks, and were fedwith high-fat diet for 12 weeks (rodent diet with
45% kcal% fat, D12451, Research Diets Inc. New Brunswick, NJ).
Ex Vivo Fat Tissue Explant Culture
The method was modified from an established adipose tissue culture tech-
nique (Delporte et al., 2002). After the mice were sacrificed, adipose tissues
(subcutaneous, visceral, perivascular) were weighted to an equal amount,
rinsed in phosphate-buffered saline (PBS), and incubated in Dulbecco’s
modified Eagle’s medium/Ham’s F12 medium (HyClone, Ogden, UT). Drugs
including rosiglitazone malate (1 mmol/l, GSK No: BRL-49653-C), GW9662
(5 mmol/l), and rabbit polyclonal antibody against mouse adiponectin (5 mg/ml)
(Zhou et al., 2008) were added individually. After 12 hr incubation, aliquots of
the mediumwere collected for either assaying adiponectin or incubating aortic112 Cell Metabolism 14, 104–115, July 6, 2011 ª2011 Elsevier Inc.rings from db/db mouse using the same protocol as mentioned above
(Figure 1A).
Fat Transplantation
The surgical procedures were approved by the Animal Experimental Ethics
Committee, CUHK. Methods were modified from several groups (Gabriely
et al., 2002; Gavrilova et al., 2000; Tran et al., 2008). To avoid rejection, donor
fat grafts were taken from db/db littermates. Mice were anaesthetized with
a mixture of 35 mg/kg ketamine and 7 mg/kg xylazine. Fat transplantation
was performed using fat pads removed from the subcutaneous dorsal area.
Fat pads were removed, cut into approximately 200 mg pieces, and kept in
saline warmed at 37C until transplantation. For each recipient mouse, a total
of 1.0 g subcutaneous fat was removed from the dorsal area; similarly sized
donor slices of fat were transplanted into the dorsal area. All mice received
subcutaneous injection of penicillin and streptomycin after surgery and were
housed in individual cages for 2 weeks before sacrifice. After sacrifice, fat
grafts were examined to detect whether there was necrosis, which was taken
as unsuccessful surgery.
Statistics
Results represent means ± SEM from different mice. Concentration-response
curves were analyzed by nonlinear regression curve fitting using GraphPad
Prism software (Version 4.0) Comparisons among groups were made using
ANOVA followed by an unpaired Student’s t test. The p values less than 0.05
were accepted to indicate statistically significant differences.
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